C-Rad ABLTS:0R44 82 Median PS Value is kr57.95 as of Jun. 29, 2026, which is 100% below its 10-year median of 0.60. GuruFocus rates LTS:0R44 with a GF Score™ of 82/100 and a GF Value™ of kr31.78 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 336 Medical Devices & Instruments companies, C-Rad AB ranks better than 60.71% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. C-Rad AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr12.66. C-Rad AB's 10-Year median PS Ratio is 4.5774. Therefore, the Median PS Value for today is kr57.95.
As of today (2026-06-29), C-Rad AB's share price is kr35.90. C-Rad AB's Median PS Value is kr57.95. Therefore, C-Rad AB's Price to Median PS Value for today is 0.62.
The historical rank and industry rank for C-Rad AB's Median PS Value or its related term are showing as below:
LTS:0R44'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4 Med: 0.6 Max: 1.3
Current: 0.62
During the past 13 years, the highest Price to Median PS Value of C-Rad AB was 1.30. The lowest was 0.40. And the median was 0.60.
LTS:0R44's Price-to-Median-PS-Value is ranked better than 60.71% of 336
companies
in the Medical Devices & Instruments industry
Industry Median: 0.71
vs LTS:0R44: 0.62
C-Rad AB (LTS:0R44) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
C-Rad AB's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
35.90
/
57.95
=
0.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-Rad AB Median PS Value Related Terms
C-Rad AB Median PS Value Historical Data
* Premium members only.
The historical data trend for C-Rad AB's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R44 vs ABT, SYK, MDT: Median PS Value Comparison
For the Medical Devices subindustry, C-Rad AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB Price-to-Median-PS-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where C-Rad AB's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 4.5774.
C-Rad AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr12.66.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-Rad AB (LTS:0R44) has a Median PS Value of kr57.95 as of Jun. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on C-Rad AB and its competitors. This is 9558% above median its historical median of 0.60. Over the past decade, C-Rad AB's Median PS Value has ranged from 0.40 to 1.30. According to the industry distribution chart, C-Rad AB ranks #132 out of 336 companies in the Medical Devices & Instruments industry, placing it in the top 39.3%.
Is C-Rad AB's Median PS Value too high?
C-Rad AB's current Median PS Value of kr57.95 is 9558% above median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 1.30. Based on the distribution chart, C-Rad AB ranks #132 out of 336 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, C-Rad AB has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Median PS Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #132 out of 336 companies for Median PS Value. This puts C-Rad AB in the upper half of its industry. The industry median Median PS Value is 0.71. Historically, C-Rad AB's own Median PS Value has ranged from 0.40 to 1.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Devices & Instruments company?
The median Median PS Value among Medical Devices & Instruments companies is 0.71, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median Median PS Value is 0.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current Median PS Value is kr57.95, which is 9558% above median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Modestly Overvalued. The stock's GF Value™ is kr31.78, compared to a current price of kr35.90 — trading 13% above its estimated fair value. The current Median PS Value is kr57.95, which is 9558% above median its 10-year median of 0.60. C-Rad AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Median PS Value is kr57.95 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr35.90 is trading 13% above its estimated GF Value™ of kr31.78.
GuruFocus considers C-Rad AB to be Modestly Overvalued.
Key valuation signals for LTS:0R44:
Median PS Value: kr57.95 (9558% above median its 10-year median of 0.60)
GF Value™: kr31.78 vs. price of kr35.90 (13% above fair value)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
82GF Score
Get the complete analysis for LTS:0R44
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
